News Medical

Hydroxychloroquine drug fails to reduce mild-moderate pain from primary hand osteoarthritis

The results of an interventional trial presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) showed that use of the disease-modifying anti-rheumatic drug ...
Morningstar

Algia Pharma Gains FDA Support to Advance Novel Non-Opioid Pain Treatment Toward a Phase 2 Clinical Trial After IND-Enabling Studies With Indication Expanded to All Mild-to ...

Positive feedback from FDA suggests an indication from perioperative pain to all mild-to-moderate acute pain, significantly expanding clinical and commercial potential IND-enabling studies currently ...

Scientists design artificial pain receptor that senses pain intensity and self-heals

All over the body are tiny sensors called nociceptors whose job is to spot potentially harmful stimuli and send warning ...

Autonomix Showcases Compelling PoC Study Clinical Data Showing Rapid and Durable Pain Relief Across All Disease Stages of Pancreatic Cancer at the 2026 ASCO Gastrointestinal ...

New subgroup analysis shows consistent, clinically meaningful pain reduction observed from Stage 2 through Stage 4 disease, including late-stage patients with otherwise limited treatment options THE ...
News Medical

Interim analysis of STOMP study finds no efficacy for tecovirimat in mild to moderate Mpox cases

The antiviral drug tecovirimat did not reduce the time to lesion resolution or have an effect on pain among adults with mild to moderate clade II mpox and a low risk of developing severe disease, ...
Business Wire

Algia Pharma Gains FDA Support to Advance Novel Non-Opioid Pain Treatment Toward a Phase 2 Clinical Trial After IND-Enabling Studies With Indication Expanded to All Mild-to ...

BOCA RATON, Fla.--(BUSINESS WIRE)--Algia Pharma, LLC (“Algia”) today announced the company has received support from the U.S. Food and Drug Administration (FDA) to advance AlgiaPak ® toward a Phase 2 ...